Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05753618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

Study acronym: REaCT-OGF
StatusRecruiting
PhasePhase 4
Started2023-04-17
View on ClinicalTrials.gov ↗

Amendment history

2026-07-06
2 amendments v4-v5
2 re-verifications since 2026-02-05, no change to tracked fields
2025-08-26
Study Status, Study Design, Contacts/Locations, References v3
Primary completion date2025-10→2026-10
Completion date2025-10→2026-10
Enrollment target240→242
Study sites1→3
2024-07-23
Study Status v2
Re-verified, no change to tracked fields
2023-04-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-04→confirmed 2023-04-17
Study sitesdetails revised at 1 of 1 site
2023-02-22
Original filing
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
Trial Details
NCT Number NCT05753618
Lead Sponsor Ottawa Hospital Research Institute
Conditions Early-stage Breast Cancer
Enrollment 242 participants
Start Date 2023-04-17
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-08